Hepatic Encephalopathy Drugs in Development, 2022 – Therapeutics Development & Assessment, Companies Involved, Drug Profiles, Product Development Milestones, Featured News & Press Releases – Yahoo Finance

DUBLIN, March 15, 2022 /PRNewswire/ — The "Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
This pipeline guide provides an overview of the Hepatic Encephalopathy pipeline landscape.
Companies Involved in Therapeutics Development
Alfasigma SpA
Axcella Health Inc
Cosmo Pharmaceuticals NV
Grifols SA
Kaleido Biosciences Inc
Neuropathix Inc
Rebiotix Inc
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Umecrine Cognition AB
Vedanta Biosciences Inc
Versantis AG
Drug Profiles
albumin (human)
rifamycin sodium CR
rifaximin SSD
Report Highlights
This pipeline guide Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 4 and 3 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).
The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)
Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered


Report Coverage


Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Companies Involved in Therapeutics Development
Drug Profiles
Dormant Projects

Discontinued Products

Product Development Milestones

Featured News & Press Releases
Jan 18, 2022: Neuropathix receives patent grant from India for its novel anti-inflammatory compounds
Jan 11, 2022: Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms
Nov 02, 2021: Axcella Therapeutics announces upcoming presentation of AXA1665 at AASLD's The Liver Meeting 2021
Jul 14, 2021: Karolinska Development's portfolio company Umecrine Cognition raises capital through a successful share issue
Jun 30, 2021: Axcella announces initiation of EMMPOWER phase 2 clinical trial of AXA1665
May 24, 2021: Positive clinical data about Axcella's AXA1665 candidate for overt hepatic encephalopathy highlighted in oral presentation at DDW 2021
Apr 22, 2021: Axcella announces upcoming oral presentation at digestive disease week (ddw) 2021
Apr 22, 2021: Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal
Dec 29, 2020: Karolinska Development increases book value of Umecrine Cognition by SEK 234 million
Oct 07, 2020: Kaleido Biosciences to present data from candidate KB174 at The Liver Meeting 2020
Oct 06, 2020: Kannalife adds to its global IP estate receiving patent grant from Canada for its novel anti-inflammatory compounds
Sep 02, 2020: Karolinska Development's portfolio company Umecrine Cognition presents results from clinical phase 2a study at AALSD International Liver meeting
Aug 27, 2020: Kaleido Biosciences announces presentation of data for microbiome metabolic therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress (EASL)
Aug 25, 2020: Kannalife receives patent grants in additional European territories
Aug 05, 2020: Axcella reports positive top-line data from AXA1665-002
For more information about this report visit https://www.researchandmarkets.com/r/cbp5ul
Media Contact:
Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/hepatic-encephalopathy-drugs-in-development-2022—therapeutics-development–assessment-companies-involved-drug-profiles-product-development-milestones-featured-news–press-releases-301503029.html
SOURCE Research and Markets
Japanese accountant Masamitsu has not travelled or gone to the cinema in years and rarely eats out. Instead, his annual salary of about $34,000 goes to support his family and has risen by just $4 a year for nearly a decade. Masamitsu's plight mirrors that of many workers at small and medium-sized firms in Japan, where the average salary in 2020 was $38,515, little changed from the 1990s and well below the average of $49,165 in countries of the Organisation for Economic Cooperation and Development (OECD).
Fast-food chain Wendy's wants to do something that Chipotle has done but McDonald's has struggled with.
Anavex Life Sciences Corp (NASDAQ: AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS1 Total score improved significantly by -14.51 for patients treated with ANAVEX2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant, corresponding to a relative improvement of 18.9% over 14 weeks. Also Read: Anavex Life Sciences Says
Saudi Arabia is in active talks with Beijing to price its oil sales to China in yuan, people familiar with the matter said, a move that would dent the U.S. dollar’s dominance of the global petroleum market and mark another shift by the world’s top crude exporter toward Asia.
The lawsuit says that changes Vanguard made benefited institutional investors, but left individual investors with taxable accounts “holding the tax bag.”
Kroger Co. is seeing customers react to soaring inflation, but those behavior changes haven’t hurt the supermarket giant’s results.
India is preparing to buy heavily discounted crude oil from its long-time ally Russia. While this may not be much, a discount on Russian crude will surely lower India’s import bill, The Times of India reported today (March 16). Every 10% increase in crude oil prices would lead to a 0.3 percentage point-widening in India’s current account deficit (CAD), and in turn, a weaker rupee, Nomura Research said in a report recently.
"I always felt like I had something to prove."
(Bloomberg) — Magdeburg in former East Germany is famous for its towering gothic cathedral, and not a lot else. It’s now about to play a key role in U.S. and European efforts to tilt the global balance of power.Most Read from BloombergUkraine Update: Russia Keeps Up Shelling Ahead of More TalksLuxury Cruise Ship Runs Aground While Leaving Caribbean PortRussia Is Spiraling Toward a $150 Billion Default NightmareUkraine’s Anti-Tank Missiles Could See Russia Shift War TacticsXi Spurs Frantic Stock
None of the proposals for lowering oil and gas prices would address the economic fundamentals that dominate the US energy industry.
Only a slim majority of Google employees now considers the company's compensation competitive with its peers.
Patients who received Biogen's Alzheimer's drug for over two years showed slower cognitive decline — leading Biogen stock to tick higher.
Ford’s Advanced Manufacturing Center has developed an interface that allows machines from different suppliers to speak to each other in the same language and operate parts of the production line autonomously. Automakers have been incorporating robotics into their manufacturing processes for decades to reduce costs and boost efficiency. The autonomous system marks the first time the Carbon 3D printers and the KUKA-built robots can talk to each other in the same language, opening limitless possibilities for other machines involved throughout the production process to collaborate.
As prices at the pump surge, GOP leaders see the suspended oil pipeline as a solution. But the answer isn't so simple.
The young electric vehicle maker struggles to bounce back as questions mount over its ability to increase production rates.
Supple chains globally remain under severe stress. Yahoo Finance live catches up with U.S. Transportation Secretary Pete Buttigieg to get his take on the situation and what the administration is doing to help.
High gas prices are here to stay due to the Ukraine war. And it may have a huge impact on the economy.
Russia’s invasion of Ukraine and Western sanctions on its oil exports threaten a supply shock that will tighten energy markets even further unless major producers increase output, the International Energy Agency said.
Berkshire Hathaway compensation levels for CEO Warren Buffett and board members remain at levels of decades past. Top executives are paid entirely in cash. There is no stock-based compensation.
The markets were already on shaky ground at the onset of 2022, but Russia’s invasion of Ukraine has ramped upped the volume significantly. Apart from specific segments that could benefit from the ongoing invasion — defense and energy stocks with little exposure to Russia readily come to mind — most segments are in risk-off mode, while the market is spooked by soaring commodity prices, with the added danger of US inflation hitting its highest level in 40 years not making the macro conditions an


Add a Comment

Your email address will not be published. Required fields are marked *